

# Julian Nam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3546139/publications.pdf>

Version: 2024-02-01

13  
papers

583  
citations

1040056

9  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

1171  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. <i>European Heart Journal</i> , 2015, 36, 100-111.	2.2	241
2	Close Contact Casting vs Surgery for Initial Treatment of Unstable Ankle Fractures in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1455.	7.4	94
3	The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years. <i>Health Technology Assessment</i> , 2016, 20, 1-158.	2.8	73
4	Systematic Review and Meta-analysis of the Benefits of Out-of-Hospital 12-Lead ECG and Advance Notification in ST-Segment Elevation Myocardial Infarction Patients. <i>Annals of Emergency Medicine</i> , 2014, 64, 176-186.e9.	0.6	51
5	Intra-Arterial Thrombolysis vs. Standard Treatment or Intravenous Thrombolysis in Adults with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>International Journal of Stroke</i> , 2015, 10, 13-22.	5.9	35
6	Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC). <i>Journal of Medical Economics</i> , 2019, 22, 625-637.	2.1	21
7	Bayesian Solutions for Handling Uncertainty in Survival Extrapolation. <i>Medical Decision Making</i> , 2017, 37, 367-376.	2.4	16
8	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 19.	1.5	14
9	Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC). <i>Journal of Medical Economics</i> , 2020, 23, 1123-1129.	2.1	14
10	Evaluation of Health in Pregnancy grants in Scotland: a natural experiment using routine data. <i>Public Health Research</i> , 2017, 5, 1-278.	1.3	10
11	Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. <i>Journal of Medical Economics</i> , 2018, 21, 47-59.	2.1	7
12	Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. <i>Current Oncology</i> , 2021, 28, 5278-5294.	2.2	5
13	A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial Protocol (ADAPT). <i>Psychosis</i> , 2016, 8, 143-155.	0.8	2